Granules Pharmaceuticals, Inc Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Granules Pharmaceuticals, Inc Pharmaceutical Import Records from India — 5 Products, $84.9M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Granules Pharmaceuticals, Inc — Pharmaceutical Importer Profile (2026) | 5 Products, $84.9M Trade | TransData Nexus

Granules Pharmaceuticals, Inc

Pharmaceutical Importer · United States · Diabetes & Endocrine Focus · $84.9M Total Trade · DGFT Verified

Granules Pharmaceuticals, Inc is a pharmaceutical importer based in United States with a total trade value of $84.9M across 5 products in 5 therapeutic categories. Based on 1,739 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Granules Pharmaceuticals, Inc sources from 1 verified Indian supplier, with Granules India Limited accounting for 100.0% of imports.

Granules Pharmaceuticals, Inc — Import Portfolio & Supplier Network

Granules Pharmaceuticals, Inc import network — 5 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Granules Pharmaceuticals, Inc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Granules India Limited	$95.0M	2,820	100.0%

Granules Pharmaceuticals, Inc sources from 1 verified Indian supplier across 1,314 distinct formulations. The sourcing is highly concentrated — Granules India Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Metformin hydrochloride tablets USP	$7.3M	167
Metformin hydrochloride tablets USP	$3.6M	91
Metformin hcl extended-release tablets	$3.3M	70
Potassium chloride extended release	$1.8M	38
Metformin hcl extended release tablets	$1.3M	25
Metformin hcl extended-release	$1.1M	22
Metformin hydrochloride extended	$846.5K	34
Metformin hcl er 500MG 500's-gpi/usa	$750.0K	15
Potassium chloride extended-release	$739.8K	15
Potassium chloride extended-release CAPS	$699.7K	15
Methocarbamol tablets, USP-	$649.5K	13
Metformin hydrochloride tablets USP	$489.8K	11
Metoprolol succinate extended-release 25MG	$489.0K	11
Metformin hcl tablets USP 850MG -	$400.0K	8
Metformin hcl extended-release tablets	$385.8K	8

Import Portfolio — Top 5 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Metformin	Diabetes & Endocrine	$59.3M	1,186	5.8%	2
2	Potassium	Nutritional Supplements	$10.4M	209	0.8%	9
3	Sertraline	CNS & Psychiatric	$7.8M	155	0.6%	9
4	Naproxen	Analgesics & Antipyretics	$4.1M	123	1.5%	12
5	Metoprolol	Cardiovascular	$3.3M	66	0.4%	16

Granules Pharmaceuticals, Inc imports 5 pharmaceutical products across 5 categories into United States totaling $84.9M.

Granules Pharmaceuticals, Inc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Granules Pharmaceuticals, Inc. is a U.S.-based pharmaceutical company specializing in the development and manufacturing of oral solid dosage forms, including tablets, capsules, and oral solutions. Established in 2014, the company operates as a wholly owned subsidiary of Granules India Limited, leveraging its parent company's extensive experience in the pharmaceutical industry. Headquartered in Chantilly, Virginia, Granules Pharmaceuticals, Inc. serves both the generic and branded pharmaceutical markets, focusing on providing high-quality and affordable healthcare solutions.

The company's facility in Chantilly is approved by the U.S. Food and Drug Administration (FDA) and the Drug Enforcement Administration (DEA), underscoring its commitment to regulatory compliance and quality standards. This facility supports both low and high-volume production, catering to a diverse range of pharmaceutical needs. Granules Pharmaceuticals, Inc. distributes its products under its own label, emphasizing cost-effectiveness and adherence to regulatory standards.

2Distribution Network

Granules Pharmaceuticals, Inc. operates a distribution network centered around its FDA and DEA-approved facility in Chantilly, Virginia. This facility serves as the primary hub for manufacturing and distributing the company's pharmaceutical products. While specific details about additional warehouse locations and logistics capabilities are not publicly disclosed, the Chantilly facility's approval by the FDA and DEA indicates a robust infrastructure capable of supporting both low and high-volume production.

3Industry Role

Granules Pharmaceuticals, Inc. functions as a pharmaceutical manufacturer and distributor within the United States. By producing and supplying oral solid dosage forms, the company plays a significant role in the pharmaceutical supply chain, providing both generic and branded medications to the U.S. market. Its operations encompass the entire process from research and development to manufacturing and distribution, ensuring a steady supply of pharmaceutical products to meet market demands.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Granules Pharmaceuticals, Inc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Granules Pharmaceuticals, Inc. imports finished pharmaceutical formulations exclusively from Granules India Limited, its parent company. This single-source dependency suggests a strategic choice to maintain control over product quality and supply chain efficiency. The substantial volume of imports—totaling $84.9 million across 1,739 shipments—indicates a stable and reliable relationship between the two entities. The concentration of imports in five therapeutic categories, with a focus on diabetes and endocrine products, reflects a targeted approach to meet specific market needs.

2Supply Chain Resilience

The resilience of Granules Pharmaceuticals, Inc.'s supply chain is closely tied to its exclusive reliance on Granules India Limited for finished pharmaceutical formulations. This centralized sourcing strategy may pose risks related to supply chain disruptions, such as production delays or regulatory challenges in India. However, the substantial volume of imports and the long-standing relationship between the two companies suggest a well-established and dependable supply chain. The focus on a limited number of therapeutic categories may also allow for more streamlined operations and quality control measures.

3Strategic Implications

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation and marketing of pharmaceutical products. The Federal Food, Drug, and Cosmetic Act (FD&C Act) provides the legal framework governing the importation of drugs, ensuring they meet standards for safety, efficacy, and quality. Pharmaceutical imports must comply with FDA regulations, including establishment registration, drug listing, and labeling requirements. The FDA also conducts inspections and enforces compliance to protect public health.

2Import Licensing & GMP

Importers of pharmaceutical products into the United States must adhere to specific licensing requirements. All foreign drug establishments whose products are imported are required to register with the FDA and list all their drug products in commercial distribution in the U.S. Additionally, imported drugs must be manufactured in compliance with Good Manufacturing Practice (GMP) standards. The FDA recognizes GMP certifications from various international bodies, including the European Union (EU) GMP, World Health Organization (WHO) GMP, and Pharmaceutical Inspection Co-operation Scheme (PIC/S). Importers must ensure that their products meet these standards to gain entry into the U.S. market.

Granules Pharmaceuticals, Inc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Granules Pharmaceuticals, Inc. focuses on importing finished pharmaceutical formulations in the diabetes and endocrine therapeutic areas, accounting for 69.9% of its total imports. This strategic emphasis aligns with the high prevalence of diabetes in the United States and the growing demand for effective treatments. The company's portfolio also includes products in the nutritional supplements (12.3%) and CNS & psychiatric (9.1%) categories, reflecting a diversified approach to meet various market needs. By concentrating on these therapeutic areas, Granules Pharmaceuticals, Inc. aims to address significant health concerns and capitalize on market opportunities.

2Sourcing Profile

Granules Pharmaceuticals, Inc. employs a sourcing strategy that relies exclusively on its parent company, Granules India Limited, for finished pharmaceutical formulations. This approach ensures consistency in product quality and leverages the manufacturing expertise of Granules India Limited. The focus on a limited number of therapeutic categories allows for specialization and efficient supply chain management. While this strategy offers control over product quality and supply, it also necessitates careful management of the relationship with the sole supplier to mitigate potential risks associated with single-source dependency.

3Market Positioning

Seller's Guide — How to Become a Supplier to Granules Pharmaceuticals, Inc

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

For new Indian suppliers, there is a realistic opportunity to engage with Granules Pharmaceuticals, Inc. by understanding the company's specific product requirements and quality standards. Diversifying the product range to include therapeutic areas not currently covered by Granules Pharmaceuticals, Inc. could present a strategic advantage. Ensuring compliance with FDA regulations and obtaining necessary certifications, such as GMP approvals from recognized bodies, are essential steps for Indian exporters seeking to supply to the U.S. market. Building a strong relationship with Granules Pharmaceuticals, Inc. through transparent communication and consistent product quality can enhance the prospects of collaboration.

2Requirements & Qualifications

Indian exporters aiming to supply Granules Pharmaceuticals, Inc. and the broader U.S. market must adhere to specific certifications and quality standards. These include obtaining GMP certifications from recognized authorities such as the European Union (EU) GMP, World Health Organization (WHO) GMP, and Pharmaceutical Inspection Co-operation Scheme (PIC/S). Additionally, compliance with FDA regulations, including establishment registration, drug listing, and labeling requirements, is mandatory. Ensuring that products meet FDA standards for safety, efficacy, and quality is crucial for successful market entry.

Frequently Asked Questions — Granules Pharmaceuticals, Inc

What products does Granules Pharmaceuticals, Inc import from India?

Granules Pharmaceuticals, Inc imports 5 pharmaceutical products across 5 categories. Top imports: Metformin ($59.3M), Potassium ($10.4M), Sertraline ($7.8M), Naproxen ($4.1M), Metoprolol ($3.3M).

Who supplies pharmaceuticals to Granules Pharmaceuticals, Inc from India?

Granules Pharmaceuticals, Inc sources from 1 verified Indian suppliers. The primary supplier is Granules India Limited (100.0% of imports, $95.0M).

What is Granules Pharmaceuticals, Inc's total pharmaceutical import value?

Granules Pharmaceuticals, Inc's total pharmaceutical import value from India is $84.9M, based on 1,739 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Granules Pharmaceuticals, Inc focus on?

Granules Pharmaceuticals, Inc imports across 5 categories. The largest: Diabetes & Endocrine (69.9%), Nutritional Supplements (12.3%), CNS & Psychiatric (9.1%).

Get Full Granules Pharmaceuticals, Inc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 3 company name variants from customs records. For current shipment-level data, contact TransData Nexus.